B. Casadei, C. Pellegrini, A. Pulsoni, G. Annechini, D. Renzo et al., 90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years, Cancer Med, vol.5, pp.1093-1100, 2016.

F. Morschhauser, J. Radford, A. Van-hoof, U. Vitolo, P. Soubeyran et al., Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma, J Clin Oncol, vol.26, pp.5156-64, 2008.

D. Rizzieri and . Zevalin, R)) (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned?, Crit Rev Oncol Hematol, vol.105, pp.5-17, 2016.

M. Tomblyn, Radioimmunotherapy for B-cell non-hodgkin lymphomas, Cancer Control, vol.19, pp.196-203, 2012.

M. S. Kaminski, A. D. Zelenetz, O. W. Press, M. Saleh, J. Leonard et al., Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas, J Clin Oncol, vol.19, pp.3918-3946, 2001.

C. W. Scholz, A. Pinto, W. Linkesch, O. Linden, A. Viardot et al., Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial, J Clin Oncol, vol.90, pp.308-321, 2013.

P. F. Ferrucci, A. Vanazzi, C. M. Grana, M. Cremonesi, M. Bartolomei et al., High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas, Br J Haematol, vol.139, pp.590-599, 2007.

A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher et al., High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma, J Clin Oncol, vol.25, pp.1396-402, 2007.

T. M. Illidge, M. Bayne, N. S. Brown, S. Chilton, M. S. Cragg et al., Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy, Blood, vol.113, pp.1412-1433, 2009.

T. M. Illidge, S. Mayes, R. Pettengell, A. T. Bates, M. Bayne et al., Fractionated (90)Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria, J Clin Oncol, vol.32, pp.212-220, 2014.

D. Hoelzer, Novel antibody-based therapies for acute lymphoblastic leukemia, Hematology Am Soc Hematol Educ Program, pp.243-252, 2011.

M. E. Juweid, Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice, J Nucl Med, vol.43, pp.1507-1536, 2002.

P. Chevallier, T. Eugene, N. Robillard, F. Isnard, F. Nicolini et al., 90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study, Lancet Haematol, vol.2, pp.108-125, 2015.

F. Kraeber-bodere, A. Pallardy, H. Maisonneuve, L. Campion, A. Moreau et al., Consolidation anti-CD22 fractionated radioimmunotherapy with (90)Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial, Lancet Haematol, vol.4, issue.16, pp.30168-30173, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01658792

P. Macor, E. Secco, S. Zorzet, C. Tripodo, C. Celeghini et al., An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies, Curr Pharm Des, vol.14, pp.2023-2062, 2008.

K. Zullo, J. E. Amengual, O. A. O'connor, and L. Scotto, Murine models in mantle cell lymphoma, Best Pract Res Clin Haematol, vol.25, pp.153-63, 2012.

M. Zandvliet, Canine lymphoma: a review, Vet Q, vol.36, pp.76-104, 2016.

A. K. Leblanc, C. N. Mazcko, and C. Khanna, Defining the value of a comparative approach to cancer drug development, Clin Cancer Res, vol.22, pp.2133-2141, 2016.

C. Saba, M. Paoloni, C. Mazcko, W. Kisseberth, J. H. Burton et al., A comparative oncology study of iniparib defines its pharmacokinetic profile and biological activity in a naturally-occurring canine cancer model, PLoS ONE, vol.11, 2016.

P. Kletting, C. Maass, S. Reske, A. J. Beer, and G. Glatting, Physiologically based pharmacokinetic modeling is essential in 90Y-labeled anti-CD66 radioimmunotherapy, PLoS ONE, vol.10, p.127934, 2015.

C. Maass, P. Kletting, D. Bunjes, B. Mahren, A. J. Beer et al., Populationbased modeling improves treatment planning before (90)Y-labeled anti-CD66 antibody radioimmunotherapy, Cancer Biother Radiopharm, vol.30, pp.285-90, 2015.

B. C. Rutgen, S. E. Hammer, W. Gerner, M. Christian, A. G. De-arespacochaga et al., Establishment and characterization of a novel canine Bcell line derived from a spontaneously occurring diffuse large cell lymphoma, Leuk Res, vol.34, pp.932-940, 2010.

M. Diab, F. Nguyen, M. Berthaud, C. Maurel, J. Gaschet et al., Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours, Vet Comp Oncol, vol.15, pp.932-51, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01414822

L. M. Matrisian, G. T. Bowden, P. Krieg, G. Furstenberger, J. P. Briand et al., The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors, Proc Natl Acad Sci, vol.83, pp.9413-9420, 1986.

P. J. Fraker and J. C. Speck, Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril, Biochem Biophys Res Commun, vol.80, pp.849-57, 1978.

T. K. Nikula, M. J. Curcio, M. W. Brechbiel, O. A. Gansow, R. D. Finn et al., A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies, Nucl Med Biol, vol.22, pp.387-90, 1995.

P. R. Tembhare, G. Marti, A. Wiestner, H. Degheidy, M. Farooqui et al., Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia, Am J Clin Pathol, vol.140, pp.813-821, 2013.

M. J. Mattes, L. B. Shih, S. V. Govindan, R. M. Sharkey, G. L. Ong et al., The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody, Int J Cancer, vol.71, pp.429-464, 1997.

B. John, B. R. Herrin, C. Raman, Y. N. Wang, K. R. Bobbitt et al., The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction, J Immunol, vol.170, pp.3534-3577, 2003.

F. Geissler, S. K. Anderson, P. Venkatesan, and O. Press, Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells, Cancer Res, vol.52, pp.2907-2922, 1992.

Y. Naruki, J. A. Carrasquillo, J. C. Reynolds, P. J. Maloney, J. M. Frincke et al., Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody, Int J Rad Appl Instrum B, vol.17, pp.201-208, 1990.

M. K. O'reilly, H. Tian, and J. C. Paulson, CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells, J Immunol, vol.186, pp.1554-63, 2011.

D. Shan and O. W. Press, Constitutive endocytosis and degradation of CD22 by human B cells, J Immunol, vol.154, pp.4466-75, 1995.

J. Lesley, R. Schulte, and J. Woods, Modulation of transferrin receptor expression and function by anti-transferrin receptor antibodies and antibody fragments, Exp Cell Res, vol.182, pp.215-248, 1989.

S. N. Rylova, C. Stoykow, D. Pozzo, L. Abiraj, K. Tamma et al., The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model, PLoS ONE, vol.13, p.195802, 2018.

R. M. Sharkey, T. M. Behr, M. J. Mattes, R. Stein, G. L. Griffiths et al., Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22, Cancer Immunol Immunother, vol.44, pp.179-88, 1997.

L. M. Bergeron, E. E. Mccandless, S. Dunham, B. Dunkle, Y. Zhu et al., Comparative functional characterization of canine IgG subclasses, Vet Immunol Immunopathol, vol.157, pp.31-41, 2014.